AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25654519 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored exercise program (6-month, twice-a-week)
Number of subjects: 60
Study 25654519 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 24015719 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (1.4 g·kg body mass⁻¹)
Number of subjects: 63
Study 24015719 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (1.1 g·kg body mass⁻¹)
Number of subjects: 63
Study 24015719 — intervention group
Group type: COMPARATOR
Intervention: Soy protein (1.4 g·kg body mass⁻¹)
Number of subjects: 63
Study 21414093 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg)
Number of subjects: 16
Study 21414093 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 16
Study 21414093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19204218 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise energy expenditure of 4 kilocalories per kilogram of body weight per week
Number of subjects: 430
Study 19204218 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise energy expenditure of 8 kilocalories per kilogram of body weight per week
Number of subjects: 430
Study 19204218 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise energy expenditure of 12 kilocalories per kilogram of body weight per week
Number of subjects: 430
Study 19204218 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control group
Number of subjects: 430
Study 17381533 — intervention group
Group type: EXPERIMENTAL
Intervention: dCa 1.5 mmol/L for three months, then dCa 1.25 mmol/L for three months (ABD-treated group)
Number of subjects: 65
Study 17381533 — intervention group
Group type: EXPERIMENTAL
Intervention: dCa 1.5 mmol/L for three months, then dCa 1.25 mmol/L for three months (sHPT-treated group)
Number of subjects: 65
Study 17381533 — intervention group
Group type: COMPARATOR
Intervention: dCa 1.75 mmol/L (ABD-control group)
Number of subjects: 65
Study 17381533 — intervention group
Group type: COMPARATOR
Intervention: dCa 1.75 mmol/L (sHPT-control group)
Number of subjects: 65
Study 15446659 — intervention group
Group type: EXPERIMENTAL
Intervention: High cognitive effort strategies during practice
Number of subjects: 29
Study 15446659 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal cognitive processing strategies during practice
Number of subjects: 29
Study 15446659 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of effortful and automatic strategies
Number of subjects: 29
Study 11222826 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone computed tomography scanning
Number of subjects: 69
Study 11222826 — intervention group
Group type: COMPARATOR
Intervention: Supine computed tomography scanning
Number of subjects: 69
Study 9688063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cmin method
Number of subjects: 0
Study 9688063 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCM method
Number of subjects: 0
Study 8090456 — intervention group
Group type: EXPERIMENTAL
Intervention: Various risk factors for graft failure
Number of subjects: 457
Study 8090456 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 457
Study 2682023 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antegrade and retrograde cardioplegia
Number of subjects: 59
Study 2682023 — intervention group
Group type: COMPARATOR
Intervention: Antegrade cardioplegia
Number of subjects: 59
Study 782955 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 17-butyrate
Number of subjects: 23
Study 782955 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 17-valerate
Number of subjects: 23
Study 30929637 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model using random forest algorithm
Number of subjects: 2064
Study 30929637 — intervention group
Group type: COMPARATOR
Intervention: Conventional US diagnosis by radiologist
Number of subjects: 2064
Study 30929637 — intervention group
Group type: COMPARATOR
Intervention: Conventional US and real-time elastography diagnosis by radiologist
Number of subjects: 2064
Study 29117238 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC/LPVr, ABC/ddI/LPVr, TDF/FTC/DRVr
Number of subjects: 228
Study 24737460 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/day)
Number of subjects: 51
Study 24737460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 23116237 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormone therapy (o-HT)
Number of subjects: 0
Study 23116237 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone therapy (t-HT)
Number of subjects: 0
Study 23116237 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21606296 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-kVp protocol with low-dose contrast material (444 mg I/kg body weight) delivered over 15 seconds
Number of subjects: 111
Study 21606296 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-kVp protocol with low-dose contrast material
Number of subjects: 111
Study 21606296 — intervention group
Group type: COMPARATOR
Intervention: 120-kVp protocol with standard-dose contrast material (600 mg I/kg) delivered over 30 seconds
Number of subjects: 111
Study 21606296 — intervention group
Group type: COMPARATOR
Intervention: 120-kVp protocol with standard-dose contrast material
Number of subjects: 111
Study 19339135 — intervention group
Group type: EXPERIMENTAL
Intervention: High counseling combined with bupropion or nicotine patch
Number of subjects: 260
Study 19339135 — intervention group
Group type: EXPERIMENTAL
Intervention: Low counseling combined with bupropion or nicotine patch
Number of subjects: 260
Study 19339135 — intervention group
Group type: EXPERIMENTAL
Intervention: High counseling
Number of subjects: 260
Study 19339135 — intervention group
Group type: EXPERIMENTAL
Intervention: Low counseling
Number of subjects: 260
Study 17412784 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (arterial oxygen saturation 80%)
Number of subjects: 10
Study 17412784 — intervention group
Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 10
Study 15389222 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab and half-dose reteplase followed by conventional medical therapy (with referral for emergency rescue PTCA allowed in selected cases)
Number of subjects: 900
Study 15389222 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab and half-dose reteplase followed by emergency angioplasty
Number of subjects: 900
Study 15389222 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab and half-dose reteplase
Number of subjects: 900
Study 11590972 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 14
Study 11590972 — intervention group
Group type: COMPARATOR
Intervention: Typical antipsychotic treatment
Number of subjects: 14
Study 9850430 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine 50 mg administered at 22.00 h
Number of subjects: 8
Study 9850430 — intervention group
Group type: COMPARATOR
Intervention: Phenylpropanolamine 50 mg administered at 10.00 h
Number of subjects: 8
Study 7522193 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 51
Study 2604449 — intervention group
Group type: EXPERIMENTAL
Intervention: Blisterfilm dressing
Number of subjects: 0
Study 2604449 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressing
Number of subjects: 0
Study 706 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa (900 mg + 225 mg benserazid daily)
Number of subjects: 18
Study 706 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa (600 mg + 150 mg benserazid)
Number of subjects: 18
Study 706 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa (300 mg + 75 mg benserazid)
Number of subjects: 18
Study 706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30262209 — intervention group
Group type: EXPERIMENTAL
Intervention: EPAP therapy
Number of subjects: 40
Study 30262209 — intervention group
Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 40
Study 29100841 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOICE for 3 months (n=100)
Number of subjects: 203
Study 29100841 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOICEplus for 24 months (n=103)
Number of subjects: 203
Study 27580832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethics officer intervention
Number of subjects: 24
Study 27580832 — intervention group
Group type: COMPARATOR
Intervention: Comparator RECs
Number of subjects: 24
Study 24476776 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor cycling
Number of subjects: 12
Study 24476776 — intervention group
Group type: COMPARATOR
Intervention: Laboratory cycling
Number of subjects: 12
Study 21036409 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 79873
Study 20817013 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg HA antigen dose
Number of subjects: 292
Study 20817013 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 15 μg HA doses
Number of subjects: 292
Study 20817013 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg HA antigen dose
Number of subjects: 292
Study 20817013 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of 30 μg HA antigen
Number of subjects: 292
Study 20817013 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine overall
Number of subjects: 292
Study 18399337 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microg intravaginally every 6 hours, maximum of 4 doses)
Number of subjects: 62
Study 18399337 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (maximum of 48 iu/min)
Number of subjects: 62
Study 15707448 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning group with a two-hour turning schedule
Number of subjects: 1772
Study 15707448 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning group with a four-hour turning schedule and pressure-reducing mattress
Number of subjects: 1772
Study 15707448 — intervention group
Group type: COMPARATOR
Intervention: Non-turning group receiving preventive care based on clinical judgement
Number of subjects: 1772
Study 12170269 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 251
Study 12170269 — intervention group
Group type: COMPARATOR
Intervention: Control (vehicle)
Number of subjects: 251
Study 10457872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 40 mg followed by 800 micrograms of misoprostol (phase 1)
Number of subjects: 398
Study 10457872 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate 50 mg/m2 followed by 800 micrograms of misoprostol (phase 1)
Number of subjects: 398
Study 10457872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg twice daily for 4 days followed by 800 micrograms of misoprostol (phase 2)
Number of subjects: 398
Study 10457872 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate followed by 800 micrograms of misoprostol (phase 2)
Number of subjects: 398
Study 8574913 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal manometry
Number of subjects: 36
Study 8574913 — intervention group
Group type: COMPARATOR
Intervention: Clinical questionnaire on gastrointestinal symptoms
Number of subjects: 36
Study 8574913 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-metry
Number of subjects: 36
Study 2467711 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost intravenous infusions starting at 0.5 ng/kg/min and increased by 0.5 ng/kg/min every 15 minutes to a maximum of 2.0 ng/kg/min for eight hours on three consecutive days with a further single infusion at week 8.
Number of subjects: 23
Study 2467711 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine starting at 30 mg daily and increased to 60 mg daily after four weeks for another 12 weeks.
Number of subjects: 23
Study 135163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate (2 mg/kg)
Number of subjects: 50
Study 135163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpirid (2.86 mg/kg)
Number of subjects: 50
Study 135163 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 50
Study 135163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31801993 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin response (10% increase)
Number of subjects: 199122
Study 31801993 — intervention group
Group type: EXPERIMENTAL
Intervention: Liability to T2D (doubling of odds)
Number of subjects: 199122
Study 31175807 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern intervention
Number of subjects: 48835
Study 31175807 — intervention group
Group type: COMPARATOR
Intervention: Usual-diet comparison group
Number of subjects: 48835
Study 28238582 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flexion knee prosthesis
Number of subjects: 960
Study 28238582 — intervention group
Group type: COMPARATOR
Intervention: Standard posterior cruciate-substituting knee prosthesis
Number of subjects: 960
Study 25197025 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 325568 (400 mg/week)
Number of subjects: 0
Study 25197025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23635996 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 30 mg kg(‐1) intravenously for 10 min, then continuous infusion at 1 g h(‐1)
Number of subjects: 64
Study 23635996 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 64
Study 21957896 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril treatment for 3 months
Number of subjects: 54
Study 19123333 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined massage-smouldering-washing therapy (MSW)
Number of subjects: 60
Study 19123333 — intervention group
Group type: COMPARATOR
Intervention: Mini-invasive surgery by arthroscopic mopping with sodium hyaluronate injection
Number of subjects: 60
Study 16297965 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to cement dust emissions
Number of subjects: 258
Study 16297965 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch tests for sensitivity to cadmium
Number of subjects: 258
Study 16297965 — intervention group
Group type: COMPARATOR
Intervention: Physical examination
Number of subjects: 258
Study 16297965 — intervention group
Group type: COMPARATOR
Intervention: Soil and plant specimens analysis
Number of subjects: 258
Study 12556921 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency flow interruption
Number of subjects: 46
Study 12556921 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 46
Study 10843828 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical aortic valve prosthesis
Number of subjects: 424
Study 9354525 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine through the left atrial route
Number of subjects: 21
Study 9354525 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine through the central venous route
Number of subjects: 21
Study 7693029 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms/kg rG‐CSF after induction therapy
Number of subjects: 41
Study 7693029 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg rG‐CSF after induction therapy
Number of subjects: 41
Study 7693029 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 micrograms/kg rG‐CSF after consolidation therapy
Number of subjects: 41
Study 7693029 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms/kg rG‐CSF after consolidation therapy
Number of subjects: 41
Study 7693029 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg rG‐CSF after consolidation therapy
Number of subjects: 41
Study 7693029 — intervention group
Group type: COMPARATOR
Intervention: No rG‐CSF after consolidation therapy
Number of subjects: 41
Study 7693029 — intervention group
Group type: EXPERIMENTAL
Intervention: Febrile neutropenia and incidence of documented infection in 5 and 10 micrograms/kg groups
Number of subjects: 41
Study 3009635 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir given as prophylaxis against infection with herpes simplex virus
Number of subjects: 19
Study 3009635 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 19
Study 3009635 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical reactivation of VZV
Number of subjects: 19
Study 3009635 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte proliferation response to VZV antigen
Number of subjects: 19
Study 3009635 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster
Number of subjects: 19
Study 3009635 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical reactivation
Number of subjects: 19
Study 29193314 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobble board training
Number of subjects: 22
Study 27144545 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with fluoropyrimidines (FP)
Number of subjects: 753
Study 27144545 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery group (patients who underwent subsequent metastasectomy)
Number of subjects: 753
Study 27144545 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgery group
Number of subjects: 753
Study 27144545 — intervention group
Group type: EXPERIMENTAL
Intervention: FP-O and FP-I regimens
Number of subjects: 753
Study 27144545 — intervention group
Group type: EXPERIMENTAL
Intervention: FP-O and FP-I combined regimens
Number of subjects: 753
Study 27144545 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type KRAS patients treated with anti-EGFR agent
Number of subjects: 753
Study 25547618 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis on and finger marker on
Number of subjects: 5
Study 25547618 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis on and finger marker off
Number of subjects: 5
Study 25547618 — intervention group
Group type: COMPARATOR
Intervention: Prosthesis off and finger marker on
Number of subjects: 5
Study 25547618 — intervention group
Group type: COMPARATOR
Intervention: Prosthesis off and finger marker off
Number of subjects: 5
Study 22956444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices (received 6 months of intensive and 12 months of less intensive practice redesign support; 2 years of revised payment; 18 months of care management support)
Number of subjects: 32
Study 22956444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices
Number of subjects: 32
Study 22956444 — intervention group
Group type: COMPARATOR
Intervention: Control practices (received yearly participation payments plus cost of PPC(®)‐PCMH™)
Number of subjects: 32
Study 22956444 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 32
Study 20538698 — intervention group
Group type: EXPERIMENTAL
Intervention: Childbirth during a 6-year follow-up in females
Number of subjects: 1786
Study 20538698 — intervention group
Group type: COMPARATOR
Intervention: Control group (males)
Number of subjects: 1786
Study 18795588 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 938
Study 18795588 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 938
Study 18795588 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg (for patients initially on RSV 10 mg who were uncontrolled)
Number of subjects: 938
Study 18795588 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch from Atorvastatin 10 mg to Rosuvastatin 10 mg (for patients initially on ATV 10 mg who were uncontrolled)
Number of subjects: 938
Study 16027027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicogenic headache group
Number of subjects: 77
Study 16027027 — intervention group
Group type: COMPARATOR
Intervention: Migraine with aura and control groups
Number of subjects: 77
Study 15071261 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE guided approach
Number of subjects: 1222
Study 15071261 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy (3 weeks of anticoagulation)
Number of subjects: 1222
Study 11026125 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Therapeutic Community (TC)
Number of subjects: 218
Study 11026125 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 218
Study 8599316 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g supplemental Ca/d as calcium carbonate (in lactating and nonlactating women)
Number of subjects: 96
Study 8599316 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactating women after weaning
Number of subjects: 96
Study 8599316 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactating women who had resumed menses
Number of subjects: 96
Study 8599316 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactating women
Number of subjects: 96
Study 8599316 — intervention group
Group type: COMPARATOR
Intervention: Nonlactating women
Number of subjects: 96
Study 8599316 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactating women and nonlactating women
Number of subjects: 96
Study 1732386 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol‐17‐propionate (CP)
Number of subjects: 0
Study 1732386 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0
Study 1732386 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone‐17‐butyrate
Number of subjects: 0
Study 1732386 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study 3903546 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange combined with prednisone
Number of subjects: 25
Study 3903546 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 25
Study 30485409 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 74
Study 30485409 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity orientation program
Number of subjects: 74
Study 30485409 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of relaxation and physical activity
Number of subjects: 74
Study 29587874 — intervention group
Group type: COMPARATOR
Intervention: SUR group (energy surplus with no exercise)
Number of subjects: 48
Study 29587874 — intervention group
Group type: EXPERIMENTAL
Intervention: SUR + ARM group (energy surplus with vigorous-intensity arm crank ergometry)
Number of subjects: 48
Study 29587874 — intervention group
Group type: EXPERIMENTAL
Intervention: SUR + MOD group (energy surplus with moderate-intensity treadmill walking)
Number of subjects: 48